biostudies-literatureVirtakoivu REuropean Union&apos;s Horizon 2020 research and innovation programCancer Research UKCancer Foundation Finland sr4205-4220https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401456biostudies-literatureUnknown27(15)<h4>Purpose</h4>Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition of the macrophage scavenger receptor Clever-1 has shown benefit in inducing CD8⁺ T-cell-mediated antitumor responses in mouse models of cancer, which supports the clinical development of Clever-1-targeting antibodies for cancer treatment.<h4>Patients and methods</h4>In this study, we analyzed the mode of action of a humanized IgG4 anti-Clever-1 antibody, FP-1305 (bexmarilimab), both <i>in vitro</i> and in patients with heavily pretreated metastatic cancer (<i>n</i> = 30) participating Clinical cancer research : an official journal of the American Association for Cancer ResearchSystemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.PMC9401456200086C53575/A2995920009696091420008129959Shetty SRobbrecht DHollmen MViitala MLonnberg Tde Jonge MJAVirtakoivu RMinchom AMa YTRannikko JHJaakkola PBono PKoivunen JMandelin JTakeda AJalkanen SSkytta TVaura FPasanen AKarvonen MKfalseSystemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.<h4>Purpose</h4>Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition of the macrophage scavenger receptor Clever-1 has shown benefit in inducing CD8⁺ T-cell-mediated antitumor responses in mouse models of cancer, which supports the clinical development of Clever-1-targeting antibodies for cancer treatment.<h4>Patients and methods</h4>In this study, we analyzed the mode of action of a humanized IgG4 anti-Clever-1 antibody, FP-1305 (bexmarilimab), both <i>in vitro</i> and in patients with heavily pretreated metastatic cancer (<i>n</i> = 30) participating 2021-01-01T00:00:00Z2021 Aug2026-05-10T06:44:19.657Z2025-04-04T13:08:55.812ZS-EPMC94014563407865110.1158/1078-0432.CCR-20-4862